NASDAQ:ADAG Adagene Q4 2025 Earnings Report $4.47 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.48 +0.01 (+0.22%) As of 07/2/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adagene EPS ResultsActual EPS-$0.04Consensus EPS -$0.28Beat/MissBeat by +$0.24One Year Ago EPSN/AAdagene Revenue ResultsActual Revenue$3.84 millionExpected Revenue$17.50 millionBeat/MissMissed by -$13.66 millionYoY Revenue GrowthN/AAdagene Announcement DetailsQuarterQ4 2025Date4/1/2026TimeBefore Market OpensConference Call DateWednesday, April 1, 2026Conference Call Time7:00AM ETUpcoming EarningsAdagene's Q1 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Adagene Earnings HeadlinesAdagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Average Rating of "Buy" from AnalystsJune 29, 2026 | americanbankingnews.comAdagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028June 22, 2026 | theglobeandmail.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect. | Weiss Ratings (Ad)Adagene to Participate in Two Upcoming Investor ConferencesMay 12, 2026 | globenewswire.comAdagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor TypesApril 17, 2026 | finance.yahoo.comAdagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor TypesApril 17, 2026 | globenewswire.comSee More Adagene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adagene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagene and other key companies, straight to your email. Email Address About AdageneAdagene (NASDAQ:ADAG) Inc., headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy. At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability. The immunome platform enables rapid identification of high-quality antibody candidates derived from healthy donor B cells, while the AI-driven design engine accelerates selection and engineering, aiming to streamline candidate advancement toward investigational new drug filings and clinical trials. Adagene operates research facilities in Suzhou and maintains an office in Cambridge, Massachusetts, serving global markets through strategic collaborations with leading pharmaceutical partners. The company’s leadership team is led by founder and CEO Dr. Ying Yan, whose expertise in antibody discovery and immuno-oncology has driven the development of its platform-based strategy. Under her guidance, Adagene has expanded its research capabilities and advanced multiple therapeutic candidates into the clinic.View Adagene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases3 Charts That Could Change the Course of Summer Trading Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
